From Fierce Biotech:
Key AZ/Targacept depression drug flunks first Phase III test
By John Carroll
November 8, 2011 — 6:49am ET
"The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's struggling R&D operation another stinging setback and walloping Targacept with a meltdown in its share value this morning."
Read the full article